The 40th Domestically Developed New Drug
World’s First Cholic Acid-Based Formula
"Leveraging Robust Sales Network and Marketing Expertise"

Medytox announced on March 23 that it will launch its injectable treatment "NUVIJU" for the improvement of moderate and severe submental fat on March 30.


NUVIJU, the 40th domestically developed new drug and the first of its kind in Korea’s medical aesthetics market, is a fat-reducing injectable that uses cholic acid (CA) as its main ingredient for the first time in the world. Unlike conventional products that use deoxycholic acid (DCA), NUVIJU utilizes cholic acid to reduce adverse reactions such as swelling and bruising. Its acidity has been adjusted to closely resemble that of the human body to minimize pain, and chemical excipients that can trigger allergies or skin irritation, such as benzyl alcohol and benzethonium chloride, have been excluded.

Medytox Newviju Injection. Medytox

Medytox Newviju Injection. Medytox

View original image

In a Phase 3 clinical trial involving 240 Korean patients with moderate to severe submental fat, evaluation showed that 88.6% of patients in the NUVIJU group achieved at least a one-grade improvement compared to the placebo group, while 46.7% achieved at least a two-grade improvement.


Medytox plans to rapidly raise brand awareness and successfully enter the market by leveraging its nationwide hospital and clinic network and identifying new Key Opinion Leaders (KOLs). The company will hold a large-scale launch symposium to highlight the clinical value and product excellence of NUVIJU and maximize strategic synergy with its other products.



A Medytox representative stated, "We will utilize our robust sales network and marketing expertise to reshape the domestic market and showcase differentiated technological and product strengths."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing